Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Dyne Therapeutics to $53 from $43 and keeps an Overweight rating on the shares. The firm notes ACHIEVE data showed 5.4mg/kg q8W DYNE-101 achieved mean splicing correction of 27% at 3 months, and improved myotonia, muscle strength and patient reported outcomes. DELIVER data showed 10.0mg/kg monthly DYNE-251 achieved 1.96% exon skipping and increased dytrophin expression to 3.22% unadjusted and to 7.64% muscle content adjusted over baseline at 6 months, and trends in functional endpoints, Piper adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Dyne Therapeutics price target raised to $43 from $39 at JPMorgan
- Dyne Therapeutics participates in a conference call with JPMorgan
- Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
- Dyne announces new Pompe disease data showing potential of FORCE platform